This paper introduces a novel method to estimate the economic impact of a reduction in A1C by utilizing a large, administrative claims database for a real-world segment of type 2 diabetes patients. The documented A1C reductions achieved through engagement with BlueStar are fractionalized and correlated with fractional cost differences associated with acute utilization, cost of supplies and pharmacy, and the cost of co-morbid complications.
January 24, 2019
External News Article:
Add reference to external site news article